Role of Bridging Therapy During Chimeric Antigen Receptor T Cell Therapy

Overview

Journal EJHaem

Specialty Hematology

Date 2022 Jul 18

PMID 35844303

Authors

Shakthi T Bhaskar

Bhagirathbhai R Dholaria

Salyka M Sengsayadeth

Bipin N Savani

Olalekan O Oluwole

Affiliations

Soon will be listed here.

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has been approved for use in several relapsed/refractory hematologic malignancies and has significantly improved outcomes for these diseases. A number of different CAR T products are now being used in clinical practice and have demonstrated excellent outcomes to those in clinical trials. However, increased real-world use of CAR T therapy has uncovered a number of barriers that can lead to significant delays in treatment. As a result, bridging therapy has become a widely used tool to stabilize or debulk disease between leukapheresis and CAR T cell administration. Here we review the available data regarding bridging therapy, with a focus on patient selection, choice of therapy, timing of therapy, and potential pitfalls.

Citing Articles

Promising Cellular Immunotherapy for Colorectal Cancer Using Classical Dendritic Cells and Natural Killer T Cells.

Singer M, Valerin J, Zhang Z, Zhang Z, Dayyani F, Yaghmai V Cells. 2025; 14(3).

PMID: 39936958 PMC: 11817869. DOI: 10.3390/cells14030166.

Recommendations for the effective use of T-cell-redirecting therapies: a Canadian consensus statement.

Lancman G, Song K, White D, Crosbie T, Sharif I, Emond M Front Oncol. 2024; 14:1446995.

PMID: 39659785 PMC: 11628543. DOI: 10.3389/fonc.2024.1446995.

Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma.

Fandrei D, Seiffert S, Rade M, Rieprecht S, Gagelmann N, Born P Blood Cancer Discov. 2024; 6(1):38-54.

PMID: 39441177 PMC: 11707513. DOI: 10.1158/2643-3230.BCD-24-0118.

Evaluation of Anti-CAR Linker mAbs for CAR T Monitoring after BiTEs/bsAbs and CAR T-Cell Pretreatment.

Grahnert A, Seiffert S, Wenk K, Schmiedel D, Boldt A, Vucinic V Biomedicines. 2024; 12(8).

PMID: 39200107 PMC: 11351819. DOI: 10.3390/biomedicines12081641.

Cytokine release syndrome after chimeric antigen receptor T cell therapy in patients with diffuse large B-cell lymphoma: a systematic review.

Rodrigues Dos Santos A, Zanini D, Andolfatto D Hematol Transfus Cell Ther. 2024; 46 Suppl 6:S306-S315.

PMID: 39089933 PMC: 11726094. DOI: 10.1016/j.htct.2024.05.005.

References

Alexander M, Culos K, Roddy J, Shaw J, Bachmeier C, Shigle T . Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration. Transplant Cell Ther. 2021; 27(7):558-570. DOI: 10.1016/j.jtct.2021.01.014. View

Abramson J, Palomba M, Gordon L, Lunning M, Wang M, Arnason J . Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852. DOI: 10.1016/S0140-6736(20)31366-0. View

Nastoupil L, Jain M, Feng L, Spiegel J, Ghobadi A, Lin Y . Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2020; 38(27):3119-3128. PMC: 7499611. DOI: 10.1200/JCO.19.02104. View

Kalos M, Levine B, Porter D, Katz S, Grupp S, Bagg A . T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011; 3(95):95ra73. PMC: 3393096. DOI: 10.1126/scitranslmed.3002842. View

Korell F, Laier S, Sauer S, Veelken K, Hennemann H, Schubert M . Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL. Cells. 2020; 9(5). PMC: 7290830. DOI: 10.3390/cells9051225. View

Gandhi U, Cornell R, Lakshman A, Gahvari Z, McGehee E, Jagosky M . Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019; 33(9):2266-2275. PMC: 6820050. DOI: 10.1038/s41375-019-0435-7. View

Gokbuget N, Stanze D, Beck J, Diedrich H, Horst H, Huttmann A . Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012; 120(10):2032-41. DOI: 10.1182/blood-2011-12-399287. View

Schuster S, Bishop M, Tam C, Waller E, Borchmann P, McGuirk J . Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018; 380(1):45-56. DOI: 10.1056/NEJMoa1804980. View

Bishop M, Maziarz R, Waller E, Jager U, Westin J, McGuirk J . Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion. Blood Adv. 2019; 3(14):2230-2236. PMC: 6650727. DOI: 10.1182/bloodadvances.2019000151. View

10.

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

11.

Crump M, Neelapu S, Farooq U, Van den Neste E, Kuruvilla J, Westin J . Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130(16):1800-1808. PMC: 5649550. DOI: 10.1182/blood-2017-03-769620. View

12.

Bhaskar S, Dholaria B, Sengsayadeth S, Savani B, Oluwole O . Role of bridging therapy during chimeric antigen receptor T cell therapy. EJHaem. 2022; 3(Suppl 1):39-45. PMC: 9175845. DOI: 10.1002/jha2.335. View

13.

Kantarjian H, Stein A, Gokbuget N, Fielding A, Schuh A, Ribera J . Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017; 376(9):836-847. PMC: 5881572. DOI: 10.1056/NEJMoa1609783. View

14.

Munshi N, Anderson Jr L, Shah N, Madduri D, Berdeja J, Lonial S . Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021; 384(8):705-716. DOI: 10.1056/NEJMoa2024850. View

15.

Till B, Jensen M, Wang J, Chen E, Wood B, Greisman H . Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008; 112(6):2261-71. PMC: 2532803. DOI: 10.1182/blood-2007-12-128843. View

16.

Hay K, Hanafi L, Li D, Gust J, Liles W, Wurfel M . Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017; 130(21):2295-2306. PMC: 5701525. DOI: 10.1182/blood-2017-06-793141. View

17.

Shah B, Ghobadi A, Oluwole O, Logan A, Boissel N, Cassaday R . KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021; 398(10299):491-502. PMC: 11613962. DOI: 10.1016/S0140-6736(21)01222-8. View

18.

Bach P . National Coverage Analysis of CAR-T Therapies - Policy, Evidence, and Payment. N Engl J Med. 2018; 379(15):1396-1398. DOI: 10.1056/NEJMp1807382. View

19.

Shah N, Highfill S, Shalabi H, Yates B, Jin J, Wolters P . CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. J Clin Oncol. 2020; 38(17):1938-1950. PMC: 7280047. DOI: 10.1200/JCO.19.03279. View

20.

Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L . Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol. 2018; 183(4):578-587. DOI: 10.1111/bjh.15567. View